Journal of Cancer Research and Practice

CASE REPORT
Year
: 2021  |  Volume : 8  |  Issue : 2  |  Page : 68--72

Dacarbazine and bevacizumab improved paraneoplastic doege–potter syndrome of malignant solitary fibrous tumor


Ching- Tso Chen1, Jen- Chieh Lee2, Shih- Chiang Huang3, Tom Wei-Wu Chen1 
1 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
3 Department of Anatomic Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan

Correspondence Address:
Dr. Tom Wei-Wu Chen
Department of Oncology, National Taiwan University Hospital, No. 7,Zhongshan South Rd., Taipei
Taiwan

Solitary fibrous tumors (SFTs) are rare soft-tissue tumors that often occur in body cavities, especially the pleural space. A subset of SFTs is histologically malignant and tends to metastasize; rarely, they may induce paraneoplastic syndromes. Doege–Potter syndrome is paraneoplastic hypoglycemia induced by oversecretion of unprocessed insulin-growth factor-2. While localized SFTs are treated mainly by surgery, the standard therapy for metastatic SFTs is lacking. Here, we present a case with metastatic malignant SFT and Doege–Potter syndrome, which was treated initially by dacarbazine and bevacizumab with a period of good clinical response.


How to cite this article:
Chen CT, Lee JC, Huang SC, Chen TW. Dacarbazine and bevacizumab improved paraneoplastic doege–potter syndrome of malignant solitary fibrous tumor.J Cancer Res Pract 2021;8:68-72


How to cite this URL:
Chen CT, Lee JC, Huang SC, Chen TW. Dacarbazine and bevacizumab improved paraneoplastic doege–potter syndrome of malignant solitary fibrous tumor. J Cancer Res Pract [serial online] 2021 [cited 2021 Oct 24 ];8:68-72
Available from: https://www.ejcrp.org/article.asp?issn=2311-3006;year=2021;volume=8;issue=2;spage=68;epage=72;aulast=Chen;type=0